Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
Biomarkers
HNSCC
Immunotherapy
PD-L1
Pembrolizumab
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
08 Apr 2024
08 Apr 2024
Historique:
received:
24
06
2023
accepted:
20
03
2024
medline:
9
4
2024
pubmed:
9
4
2024
entrez:
8
4
2024
Statut:
epublish
Résumé
The KEYNOTE-048 trial showed that pembrolizumab-based first-line treatment for R/M HNSCC led to improved OS in the PD-L1 CPS ≥ 1 population when compared to the EXTREME regimen. However, the R/M HNSCC real-world population is generally frailer, often presenting with multiple comorbidities, worse performance status and older age than the population included in phase III clinical trials. This is a retrospective, single-centre analysis of patients with R/M HNSCC treated with pembrolizumab-based first-line treatment. From February 2021 to March 2023, 92 patients were treated with pembrolizumab-based first-line treatment. Patients treated with pembrolizumab-based chemoimmunotherapy had better ECOG PS and younger age than those treated with pembrolizumab monotherapy. Median PFS and OS were 4 months and 8 months, respectively. PFS was similar among patients treated with pembrolizumab-based chemoimmunotherapy and pembrolizumab monotherapy, while patients treated with pembrolizumab monotherapy had worse OS (log-rank p =.001, HR 2.7). PFS and OS were improved in patients with PD-L1 CPS > = 20 (PFS: log-rank p =.005, HR 0.50; OS: log-rank p =.04, HR 0.57). Patients with higher ECOG PS scores had worse PFS and OS (PFS, log-rank p =.004; OS, log-rank p = 6e-04). In multivariable analysis, ECOG PS2 was associated with worse PFS and OS. PFS in our real-world cohort was similar to the KEYNOTE-048 reference while OS was numerically inferior. A deeper understanding of clinical variables that might affect survival outcomes of patients with R/M HNSCC beyond ECOG PS and PD-L1 CPS is urgently needed.
Sections du résumé
BACKGROUND
BACKGROUND
The KEYNOTE-048 trial showed that pembrolizumab-based first-line treatment for R/M HNSCC led to improved OS in the PD-L1 CPS ≥ 1 population when compared to the EXTREME regimen. However, the R/M HNSCC real-world population is generally frailer, often presenting with multiple comorbidities, worse performance status and older age than the population included in phase III clinical trials.
METHODS
METHODS
This is a retrospective, single-centre analysis of patients with R/M HNSCC treated with pembrolizumab-based first-line treatment.
RESULTS
RESULTS
From February 2021 to March 2023, 92 patients were treated with pembrolizumab-based first-line treatment. Patients treated with pembrolizumab-based chemoimmunotherapy had better ECOG PS and younger age than those treated with pembrolizumab monotherapy. Median PFS and OS were 4 months and 8 months, respectively. PFS was similar among patients treated with pembrolizumab-based chemoimmunotherapy and pembrolizumab monotherapy, while patients treated with pembrolizumab monotherapy had worse OS (log-rank p =.001, HR 2.7). PFS and OS were improved in patients with PD-L1 CPS > = 20 (PFS: log-rank p =.005, HR 0.50; OS: log-rank p =.04, HR 0.57). Patients with higher ECOG PS scores had worse PFS and OS (PFS, log-rank p =.004; OS, log-rank p = 6e-04). In multivariable analysis, ECOG PS2 was associated with worse PFS and OS.
CONCLUSIONS
CONCLUSIONS
PFS in our real-world cohort was similar to the KEYNOTE-048 reference while OS was numerically inferior. A deeper understanding of clinical variables that might affect survival outcomes of patients with R/M HNSCC beyond ECOG PS and PD-L1 CPS is urgently needed.
Identifiants
pubmed: 38589857
doi: 10.1186/s12885-024-12155-3
pii: 10.1186/s12885-024-12155-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
430Informations de copyright
© 2024. The Author(s).
Références
Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92. https://doi.org/10.1038/s41572-020-00224-3 . Erratum in: Nat Rev Dis Primers. 2023;9(1):4. PMID: 33243986; PMCID: PMC7944998.
Chow LQM. Head and Neck Cancer. N Engl J Med. 2020;382(1):60–72. https://doi.org/10.1056/NEJMra1715715 . PMID: 31893516.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D. KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915–1928. https://doi.org/10.1016/S0140-6736(19)32591-7 . Epub 2019 Nov 1. Erratum in: Lancet. 2020;395(10220):272. Erratum in: Lancet. 2020;395(10224):564. Erratum in: Lancet. 2021;397(10291):2252. PMID: 31679945.
Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Lin J, Gumuscu B, Swaby RF, Rischin D. Pembrolizumab with or without chemotherapy in recurrent or metastatic Head and Neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. J Clin Oncol. 2023;41(4):790–802. Epub 2022 Oct 11. PMID: 36219809; PMCID: PMC9902012.
doi: 10.1200/JCO.21.02508
pubmed: 36219809
Machiels JP, René Leemans C, Golusinski W, Grau C, Licitra L, Gregoire V. EHNS Executive Board. Electronic address: secretariat@ehns.org; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org; ESTRO Executive Board. Electronic address: info@estro.org. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1462–75. Epub 2020 Oct 23. PMID: 33239190.
doi: 10.1016/j.annonc.2020.07.011
pubmed: 33239190
Corrêa GT, Bandeira GA, Cavalcanti BG, Santos FB, Rodrigues Neto JF, Guimarães AL, Haikal DS, De Paula AM. Analysis of ECOG performance status in head and neck squamous cell carcinoma patients: association with sociodemographical and clinical factors, and overall survival. Support Care Cancer. 2012;20(11):2679-85. https://doi.org/10.1007/s00520-012-1386-y . PMID: 22314971.
Szturz P, Bossi P, Vermorken JB. Systemic treatment in elderly head and neck cancer patients: recommendations for clinical practice. Curr Opin Otolaryngol Head Neck Surg. 2019;27(2):142–50. https://doi.org/10.1097/MOO.0000000000000526 .
doi: 10.1097/MOO.0000000000000526
pubmed: 30694914
Botticelli A, Pomati G, Cirillo A, Mammone G, Ciurluini F, Cerbelli B, Sciattella P, Ralli M, Romeo U, De Felice F, Catalano C, Vullo F, Della Monaca M, Amirhassankhani S, Tomao S, Valentini V, De Vincentiis M, Tombolini V, Della Rocca C, Polimeni A, di Gioia C, Corsi A, D’Amati G, Mezi S, Marchetti P. Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era. J Transl Med. 2021;19(1):303. https://doi.org/10.1186/s12967-021-02975-3 . PMID: 34253248; PMCID: PMC8274020.
doi: 10.1186/s12967-021-02975-3
pubmed: 34253248
pmcid: 8274020
https:// www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf .
Dzienis MR, Cundom JE, Fuentes CS, Hansen AR, Nordlinger MJ, Pastor AV, Oppelt P, Neki A, Gregg RW, Lima IPF, Franke FA, da Cunha Junior GF, Tseng JE, Loree T, Joshi AJ, Mccarthy JS, Naicker N, Sidi Y, Gumuscu B, De Castro Jr. G. 651O - pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): phase VI KEYNOTE-B10 study. Ann Oncol. 2022;33(suppl7):S295–322. https://doi.org/10.1016/annonc/annonc1056 .
doi: 10.1016/annonc/annonc1056
Wagner SM, Magnes T, Melchardt T, Kiem D, Weiss L, Neureiter D, Wagner C, Aretin MB, Nemec S, Gamerith G, Pall G, Greil R, Fuereder T. Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer. Anticancer Res. 2023;43(3):1273–1282. https://doi.org/10.21873/anticanres.16274 . PMID: 36854497.
Black CM, Wang L, Ramakrishnan K, Turzhitsky V. Real-world time on treatment analysis of pembrolizumab treated recurrent/metastatic head & neck squamous cell carcinoma (R/M HNSCC) patients stratified by ECOG PS in the United States. J Clin Oncol 2022 40:16_suppl, e18007–18007.
Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, Daste A, Koralewski P, Zurawski B, Taberna M, Saba NF, Mak M, Kawecki A, Girotto G, Alvarez Avitia MA, Even C, Toledo JGR, Guminski A, Müller-Richter U, Kiyota N, Roberts M, Khan TA, Miller-Moslin K, Wei L, Argiris A. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line treatment for Recurrent/Metastatic squamous cell carcinoma of the Head and Neck: The Final results of CheckMate 651. J Clin Oncol. 2023;41(12):2166–80. Epub 2022 Dec 6. PMID: 36473143; PMCID: PMC10115555.
doi: 10.1200/JCO.22.00332
pubmed: 36473143
Psyrri A, Fayette J, Harrington K, Gillison M, Ahn MJ, Takahashi S, Weiss J, Machiels JP, Baxi S, Vasilyev A, Karpenko A, Dvorkin M, Hsieh CY, Thungappa SC, Segura PP, Vynnychenko I, Haddad R, Kasper S, Mauz PS, Baker V, He P, Evans B, Wildsmith S, Olsson RF, Yovine A, Kurland JF, Morsli N, Seiwert TY, KESTREL Investigators. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. Ann Oncol. 2023;34(3):262–74. https://doi.org/10.1016/j.annonc.2022.12.008 . Epub 2022 Dec 16. PMID: 36535565.
doi: 10.1016/j.annonc.2022.12.008
pubmed: 36535565
Foster CC, Couey MA, Kochanny SE, Khattri A, Acharya RK, Tan YC, Brisson RJ, Leidner RS, Seiwert TY. Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors. Cancer. 2021;127(24):4565–73. https://doi.org/10.1002/cncr.33780 . Epub 2021 Sep 21. PMID: 34547103.
doi: 10.1002/cncr.33780
pubmed: 34547103
Conroy M, Naidoo J. Immune-related adverse events and the balancing act of immunotherapy. Nat Commun. 2022;13(1):392. https://doi.org/10.1038/s41467-022-27960-2 . Published 2022 Jan 19.
doi: 10.1038/s41467-022-27960-2
pubmed: 35046403
pmcid: 8770784
Yadav K, Lewis RJ. Immortal Time Bias in Observational studies. JAMA. 2021;325(7):686–7. https://doi.org/10.1001/jama.2020.9151 .
doi: 10.1001/jama.2020.9151
pubmed: 33591334
Dall’Olio FG, Di Nunno V, Massari F. Immortal Time Bias question in the Association between toxicity and outcome of Immune Checkpoint inhibitors. J Clin Oncol. 2020;38(1):105–6. https://doi.org/10.1200/JCO.19.01728 .
doi: 10.1200/JCO.19.01728
pubmed: 31675246